Key facts
- It has raised $27.9M.
- Notable investors include Wuhan Hi-Tech, Wuhan Huagong Venture Capital, Haide Zeguang Investment, Homsun Capital, SDIC Venture Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Genevoyager
- ·The full record, as it builds
Funding rounds
No funding rounds for Genevoyager are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genevoyager
Developer of biopharmaceutical development and production systems designed for gene therapy and vaccine research purposes. The company offers large-scale AAV vector preparation technology, cGMP-compliant protein and viral vector manufacturing facilities, integrated CRO/CDMO services, proprietary recombinant bacmid systems for stable yield, liver-specific gene expression promoters, and advanced quality control workflows, thereby enabling biotechnology firms and clinical research organizations to accelerate therapeutic development, ensure regulatory compliance, improve production scalability, and support innovative treatments for genetic disorders and protein-based therapies.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2022
- Employees
- 300
- Website
- genevoyager.com/
- Ownership
- Privately Held (backing)
Genevoyager doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genevoyager shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genevoyager in its N-PORT filings yet. We sweep new filings monthly.